I. Andrieux-Meyer

发表

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

G. Cooke, S. Bhagani, A. Hill, 2015, Journal of virus eradication.

The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing

R. Peeling, P. Easterbrook, M. Colombo, 2017, BMC Infectious Diseases.

Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study

P. Easterbrook, J. Chhatwal, S. Murad, 2021, BMJ Open.

Why it’s time to say goodbye to stavudine ... everywhere

S. Collins, E. Goemaere, P. Clayden, 2012 .

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir

P. Denti, M. Cotton, H. McIlleron, 2020, Antimicrobial Agents and Chemotherapy.

Getting HIV Treatment to the Most People

N. Ford, H. Bygrave, C. Ferreyra, 2012, Science.

Preferred antiretroviral drugs for the next decade of scale up

N. Ford, C. Katlama, P. Cahn, 2012, Journal of the International AIDS Society.

Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings

N. Ford, A. Calmy, I. Andrieux-Meyer, 2011, HIV/AIDS.

Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low‐ to high‐income settings: making sure no one is left behind

L. Mendão, I. Andrieux-Meyer, Céline Grillon, 2018, Journal of the International AIDS Society.

Disparity in market prices for hepatitis C virus direct-acting drugs.

S. Hamid, I. Andrieux-Meyer, E. S. A. de Araújo, 2015, The Lancet. Global health.

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.

R. Peeling, J. Ward, Rakesh Aggarwal, 2019, The lancet. Gastroenterology & hepatology.

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.

N. Ford, S. Jaffar, J. Klausner, 2019, The Lancet. Infectious diseases.

Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study

M. Cotton, E. Capparelli, H. Rabie, 2021, Journal of acquired immune deficiency syndromes.

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

M. Peeters, F. Liégeois, E. Delaporte, 2004, The Lancet.

Field Assessment of Generic Antiretroviral Drugs: A Prospective Cohort Study in Cameroon

F. Liégeois, E. Delaporte, A. Calmy, 2005, Antiviral therapy.

Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access

J. Rockstroh, M. Klein, A. Scheibe, 2017, Hepatology, Medicine and Policy.

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

N. Ford, A. Calmy, I. Andrieux-Meyer, 2012, HIV/AIDS.

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

Edward J. Mills, Sally Hargreaves, N. Ford, 2013, AIDS.

Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis

Edward J Mills, Sally Hargreaves, N. Ford, 2013, AIDS.

Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.

N. Ford, A. Verster, A. Hill, 2015, The International journal on drug policy.

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis

N. Ford, L. Mofenson, A. Calmy, 2011, AIDS.

Population pharmacokinetics of ethambutol in African children: a pooled analysis

H. Zar, P. Denti, M. Cotton, 2022, The Journal of antimicrobial chemotherapy.

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

S. Yerly, S. Tan, S. Murad, 2021, The lancet. Gastroenterology & hepatology.

Efficacy and Safety of Ravidasvir Plus Sofosbuvir in Chronic Hepatitis C Infected Subjects Without Cirrhosis or with Compensated Cirrhosis: Interim Analysis Results of a Two-Stage, Open-Label, Multicentre, Phase 2/3 Trial

S. Yerly, S. Tan, S. Murad, 2020, SSRN Electronic Journal.

Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver–child dyads’ perspective

A. Kekitiinwa, C. Nöstlinger, Anke Rotsaert, 2023, Therapeutic advances in infectious disease.

Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa

H. Bygrave, J. Ousley, D. Maman, 2018, AIDS.

Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial

S. Murad, K. Goh, A. Kamarulzaman, 2018 .